Stellar Pharmaceuticals
Français        Contact Us     1-800-639-0643          

Contact Us

Stellar Pharmaceuticals Inc.
544 Egerton St
London ON, N5W 3Z8
T: 1-800-639-0643
F: 519-434-4382

Press Releases

 1    
Release Date Title (Click to read)
Jan 2, 2013 Stellar Pharmaceuticals Announces Name & Ticker Change to Tribute Pharmaceuticals Canada Inc. and 'TBUFF'; Issues Letter to Shareholders
Nov 28, 2012 Stellar Pharmaceuticals Appoints Chief Scientific Officer to Support Growing Product Portfolio
Nov 13, 2012 Stellar Pharmaceuticals Shows Strong Third Quarter Revenue Growth to $3.2 Million
Nov 13, 2012 Stellar Pharmaceuticals Shows Strong Third Quarter Revenue Growth to $3.2 Million
Oct 4, 2012 Stellar Pharmaceuticals Launches New Migraine Treatment, CAMBIA(R), in $150 Million Canadian Prescription Migraine Market
Aug 23, 2012 Stellar Pharmaceuticals Enters Into a Partnership With Pfizer Canada Inc. to Promote Gelfoam(R) in Canada
Aug 14, 2012 Stellar Pharmaceuticals Reports Second Quarter and First Half 2012 Financial Results
Jun 20, 2012 Stellar Pharmaceuticals Acquires the Exclusive Rights to Collatamp G(R) in Canada
Jun 11, 2012 Stellar Pharmaceuticals to Present at the Bloom Burton Investor Conference June 21
May 15, 2012 Stellar Pharmaceuticals Reports First Quarter 2012 Financial Results
May 14, 2012 Stellar Pharmaceuticals Inc. Secures US$6.0 Million Term Loan to Support Market Growth
Apr 2, 2012 Stellar Pharmaceuticals Strong Product Sales in 2011; Builds for the Future
Mar 29, 2012 Stellar Pharmaceuticals Inc.: Shareholder Early Warning News Release
Mar 21, 2012 Stellar Pharmaceuticals Inc. Announces Correction to Conference Call Access Number Dated March 19, 2012
Mar 19, 2012 Stellar to Hold Conference Call re Health Canada Approval of CAMBIA(R) for the Treatment of Acute Migraines
Mar 16, 2012 Health Canada Approves CAMBIA(R) for the Treatment of Acute Migraine
Jan 26, 2012 Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America
Jan 3, 2012 Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis
Jan 3, 2012 Stellar Pharmaceuticals Inc.: Conference Call
Jan 3, 2012 Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis
 1    
Copyright © 2011 Stellar Pharmaceuticals Inc. All rights reserved.